UK biopharmaceuticals research projects win £4m of funding
Aim to strengthen UK’s position in the sector
These projects will provide the foundations for the UK pharmaceutical sector to strengthen its position in the biopharmaceutical sector to the benefit of society and the economy.
The Bioprocessing Research Industry Club (BRIC), a Biotechnology and Biological Sciences Research Council (BBSRC)-led public-private partnership with the Engineering and Physical Sciences Research Council (EPSRC) and a consortium of 16 industrial partners, including companies such as Pfizer, GlaxoSmithKline, Lonza and Biodesign, is providing £4m to fund the projects.
This money will go to six research projects, eight PhD studentships and a Skills Development School for early stage researchers.
The projects will address current challenges in bioprocessing, while the PhD studentships and Skills Development School will ensure that the next generation of researchers have the technical knowledge and personal skills to secure future UK success in producing biopharmaceuticals.
Each PhD student will spend six months or a year on placement with a partner company where they will develop an understanding of the challenges involved in producing biological medicines on a commercial scale.
Biopharmaceuticals such as vaccines, monoclonal antibodies, hormones and peptide therapeutics, make up over a third of the medicines currently under development and the number of licensed biological medicines is expected to grow by 20% a year.
You may also like
Manufacturing
etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage
etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
Manufacturing
Lonza expands AAV offering with Xcite AAV stable Producer Cell Line platform to idustrialise Viral Vector Manufacturing
New technology demonstrates superior performance versus transient transfection in clinically relevant customer gene of interest and engineered capsid, enabling scalable and cost-effective AAV manufacturing. Launch reflects Lonza’s deep expertise in cell line development, viral vector manufacturing, and platform industrialisation built over decades of supporting complex biologics
Manufacturing
Piramal Pharma Solutions unveils state-of-the-art payload-linker suite at its Riverview, Michigan facility
The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialised solutions for payload-linkers. This cutting-edge suite will significantly enhance the company’s ability to support global payload-linker development and manufacturing and help partners bring complex therapies like antibody-drug conjugates (ADCs) and other bioconjugates to market
Research & Development
VoxCell BioInnovation and adMare partner to validate bioprinted vascularised cancer tissue models for antibody therapy development
The pair have announced a research collaboration using VoxCell's human-relevant bioprinted vascularised cancer tissue models to validate a novel antibody-based immune-modulating therapy, as the FDA advances plans to reduce animal testing for monoclonal antibodies through New Approach Methodologies